APA (7th ed.) Citation

DC, B., KVA, M., ALR, R., AA, d. S. B., ASL, B., MRF, C., . . . MVG, L. (2026). Dihydroartemisinin-piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): An open-label, single-centre, randomised clinical trial. The Lancet. Infectious diseases. https://doi.org/10.1016/S1473-3099(26)00139-8

Chicago Style (17th ed.) Citation

DC, Baía-da-Silva, et al. "Dihydroartemisinin-piperaquine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium Vivax Malaria with Concurrent or Delayed High-dose Primaquine in Brazil (Curavivax): An Open-label, Single-centre, Randomised Clinical Trial." The Lancet. Infectious Diseases 2026. https://doi.org/10.1016/S1473-3099(26)00139-8.

MLA (9th ed.) Citation

DC, Baía-da-Silva, et al. "Dihydroartemisinin-piperaquine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium Vivax Malaria with Concurrent or Delayed High-dose Primaquine in Brazil (Curavivax): An Open-label, Single-centre, Randomised Clinical Trial." The Lancet. Infectious Diseases, 2026, https://doi.org/10.1016/S1473-3099(26)00139-8.